| 8.375 -0.345 (-3.96%) | 01-28 11:18 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.15 | 1-year : | 13.02 |
| Resists | First : | 9.54 | Second : | 11.15 |
| Pivot price | 8.22  |
|||
| Supports | First : | 7.95 | Second : | 6.96 |
| MAs | MA(5) : | 8.75  |
MA(20) : | 8.02 |
| MA(100) : | 7.76 |
MA(250) : | 7.05 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 62.3 |
D(3) : | 66.7 |
| RSI | RSI(14): 55.9 |
|||
| 52-week | High : | 9.54 | Low : | 3.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DERM ] has closed below upper band by 35.4%. Bollinger Bands are 89.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.78 - 8.82 | 8.82 - 8.87 |
| Low: | 8.18 - 8.23 | 8.23 - 8.27 |
| Close: | 8.65 - 8.72 | 8.72 - 8.79 |
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Fri, 23 Jan 2026
Journey Medical Corp Entered Into Sales Agreement To Offer And Sell Up To 3.75 Million Shares Of Common Stock - TradingView
Thu, 22 Jan 2026
Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed - Seeking Alpha
Sun, 18 Jan 2026
How Journey Medical Corporation (DERM) Affects Rotational Strategy Timing - Stock Traders Daily
Wed, 14 Jan 2026
Journey Medical (NASDAQ:DERM) Trading 3.4% Higher - Here's What Happened - MarketBeat
Wed, 14 Jan 2026
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 21 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 31.3 (%) |
| Held by Institutions | 41.2 (%) |
| Shares Short | 2,440 (K) |
| Shares Short P.Month | 2,390 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.98 |
| Profit Margin | -14.6 % |
| Operating Margin | -8.7 % |
| Return on Assets (ttm) | -4.6 % |
| Return on Equity (ttm) | -47.1 % |
| Qtrly Rev. Growth | 20.5 % |
| Gross Profit (p.s.) | 1.85 |
| Sales Per Share | 2.8 |
| EBITDA (p.s.) | -0.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -24.49 |
| PEG Ratio | 0 |
| Price to Book value | 8.74 |
| Price to Sales | 3.04 |
| Price to Cash Flow | -46.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|